<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2021/10/moderna-jj-booster-e1634837028397.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2021/10/moderna-jj-booster-e1634837028397.jpg"/></p>
<p>Moderna Inc.（纳斯达克股票代码：MRNA）周四股价暴跌超过 14％，原因是公司宣布大幅削减年度研发费用。</p>
<p>这家生物科技巨头透露，计划从 2027 年开始削减 11 亿美元的研发预算，将年度支出从 2024 年的 48 亿美元降至 2027 年的 36 至 38 亿美元之间。</p>
<p>这一决定源于战略努力，优先考虑其商业组合，现在将专注于肿瘤学、罕见疾病和首创非呼吸道疫苗。</p>
<p>作为这一调整的一部分，Moderna 将停止五个项目，包括其 KRAS 抗原特异性疗法和地方性 HCoV 疫苗。</p>
<p>这一宣布时机对于 Moderna 来说至关重要，因为公司正努力应对具有挑战性的市场环境。</p>
<p>公司面临着 COVID-19 疫苗销售下滑的阻力，其 2024 年全年营收指引从之前的 40 亿美元下调至 30-35 亿美元，较之前的预期大幅下降。</p>
<h2>RSV 批准</h2>
<p>尽管营收下调，Moderna 在扩大疫苗组合方面仍在取得进展。</p>
<p>欧洲药品管理局最近认可了该公司针对奥密克戎变种的更新 COVID-19 疫苗，并且 Moderna 已获得其 RSV 疫苗 mRESVIA 在包括美国和欧洲在内的多个地区的监管批准。</p>
<p>然而，RSV 疫苗市场预计将小于预期，给 Moderna 的营收预测增加了另一层不确定性。</p>
<p>Moderna 的财务状况仍然是投资者关注的焦点。公司 2024 年第二季度报告的根据通用会计准则（GAAP）的净亏损为 13 亿美元，略好于去年同期的 14 亿美元亏损。</p>
<p>公司第二季度总营收为 2.41 亿美元，超出分析师预期，但反映了后疫情时代持续面临的挑战。</p>
<h2>两年现金储备</h2>
<p>现金燃烧速度仍然显著，截至 2024 年 6 月 30 日，Moderna 的现金头寸下降至 108 亿美元，较第一季度末的 122 亿美元下降。</p>
<p>随着运营费用仍然居高不下，Moderna 的现金储备预计将支撑公司约两年时间，这给管理层带来了压力，要求其推动产品管线并通过新产品推出推动营收增长。</p>
<p>公司的估值指标表明，尽管 Moderna 的股票并未被高估，但当前市场情绪谨慎。</p>
<p>股票的市盈率（P/E）难以衡量，但其企业价值与营收（EV/营收）比率为 4.16，表明投资者仍在给予 Moderna 未来潜在增长溢价，尽管最近遭遇挫折。</p>
<p>随着 Moderna 继续面临来自呼吸道疫苗市场竞争压力以及其肿瘤学和罕见疾病项目的不确定性，前方道路充满挑战。</p>
<p>现在，让我们来看看图表对 Moderna 股价走势的看法。技术指标可能进一步揭示最近的下跌是买入机会还是继续下行风险的信号。</p>
<h2>67 美元支撑位能否保持？</h2>
<p>自 2021 年底股价飙升至 480 美元以上以来，Moderna 股价一直处于持续下跌趋势。去年 11 月暴跌至 70 美元以下后，股价经历了一轮强劲的中期反弹，使其在今年 5 月达到 170 美元水平，但自那时以来已经下跌了一半，目前交易在 80 美元以下。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/MRNA_2024-09-12_18-36-08-1024x555.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/MRNA_2024-09-12_18-36-08-1024x555.png"/></p>
<p>来源：TradingView</p>
<p>最近的急剧下跌使 Moderna 股价在各个时间框架上变得疲弱，今天的暴跌将进一步加剧这种情况。因此，将今天的走势视为买入机会的投资者必须谨慎行事。只有在 Moderna 股价再次在去年底支撑位 67 美元附近得到支撑时，才应考虑持有多头头寸。</p>
<p>根据今天的消息对该股持悲观态度的交易者应该寻找股价回升至 70 美元以上后再建立空头头寸。如果股价跌破 67 美元的中期支撑位，将会变得非常疲弱，并可能暴跌至更低水平。</p>
<p>本文来源于 Invezz</p>

MRNA

<p>Moderna Inc.（纳斯达克股票代码：MRNA）宣布大幅削减研发预算后，股价下跌了 14％，将年度支出从 2024 年的 28 亿美元削减至 2027 年的 16 亿至 18 亿美元。该公司将停止五个项目，专注于肿瘤学和罕见疾病。尽管其疫苗最近获得监管批准，但 COVID-19 销售下降以及 2024 年第二季度预计出现 13 亿美元的普通会计净亏损，引发了对其财务健康状况的担忧。投资者对股票持续下跌趋势感到谨慎，受到竞争压力和管道不确定性的影响</p>

<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2021/10/moderna-jj-booster-e1634837028397.jpg" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2021/10/moderna-jj-booster-e1634837028397.jpg"/></p>
<p>Moderna Inc. (NASDAQ: MRNA) saw its stock plunge more than 14% on Thursday, following the company’s announcement of significant cuts to its annual research and development (R&amp;D) expenses.</p>
<div class="lb-trans"><p>Moderna Inc.（纳斯达克股票代码：MRNA）周四股价暴跌超过 14％，原因是公司宣布大幅削减年度研发费用。</p>
</div><p>The biotech giant revealed plans to slash its R&amp;D budget by $1.1 billion starting in 2027, reducing annual expenditure from $4.8 billion in 2024 to between $3.6 billion and $3.8 billion by 2027.</p>
<div class="lb-trans"><p>这家生物科技巨头透露，计划从 2027 年开始削减 11 亿美元的研发预算，将年度支出从 2024 年的 48 亿美元降至 2027 年的 36 至 38 亿美元之间。</p>
</div><p>This decision stems from a strategic effort to prioritize its commercial portfolio, which will now focus on oncology, rare diseases, and first-in-class non-respiratory vaccines.</p>
<div class="lb-trans"><p>这一决定源于战略努力，优先考虑其商业组合，现在将专注于肿瘤学、罕见疾病和首创非呼吸道疫苗。</p>
</div><p>As part of this realignment, Moderna will discontinue five programs, including its KRAS antigen-specific therapy and Endemic HCoV vaccine.</p>
<div class="lb-trans"><p>作为这一调整的一部分，Moderna 将停止五个项目，包括其 KRAS 抗原特异性疗法和地方性 HCoV 疫苗。</p>
</div><p>This announcement comes at a critical time for Moderna as it seeks to navigate a challenging market environment.</p>
<div class="lb-trans"><p>这一宣布时机对于 Moderna 来说至关重要，因为公司正努力应对具有挑战性的市场环境。</p>
</div><p>The company has faced headwinds from declining COVID-19 vaccine sales, with its full-year 2024 revenue guidance being revised down to $3.0-$3.5 billion, a notable drop from its earlier projection of $4 billion.</p>
<div class="lb-trans"><p>公司面临着 COVID-19 疫苗销售下滑的阻力，其 2024 年全年营收指引从之前的 40 亿美元下调至 30-35 亿美元，较之前的预期大幅下降。</p>
</div><h2>RSV Approval</h2>
<div class="lb-trans"><h2>RSV 批准</h2>
</div><p>Despite the downward revision in revenue, Moderna continues to make progress in expanding its vaccine portfolio.</p>
<div class="lb-trans"><p>尽管营收下调，Moderna 在扩大疫苗组合方面仍在取得进展。</p>
</div><p>The European Medicines Agency recently endorsed the company’s updated COVID-19 vaccine targeting the Omicron variant, and Moderna has secured regulatory approvals for its RSV vaccine, mRESVIA, across several regions, including the U.S. and Europe.</p>
<div class="lb-trans"><p>欧洲药品管理局最近认可了该公司针对奥密克戎变种的更新 COVID-19 疫苗，并且 Moderna 已获得其 RSV 疫苗 mRESVIA 在包括美国和欧洲在内的多个地区的监管批准。</p>
</div><p>However, the market for RSV vaccines is expected to be smaller than anticipated, adding another layer of uncertainty to Moderna’s revenue projections.</p>
<div class="lb-trans"><p>然而，RSV 疫苗市场预计将小于预期，给 Moderna 的营收预测增加了另一层不确定性。</p>
</div><p>Moderna’s financial health remains a point of concern for investors. The company reported a GAAP net loss of $1.3 billion for Q2 2024, slightly better than the $1.4 billion loss in the same period last year.</p>
<div class="lb-trans"><p>Moderna 的财务状况仍然是投资者关注的焦点。公司 2024 年第二季度报告的根据通用会计准则（GAAP）的净亏损为 13 亿美元，略好于去年同期的 14 亿美元亏损。</p>
</div><p>The company reported $241 million in total revenue for the quarter, beating analyst expectations but reflecting the ongoing challenges in the post-pandemic landscape.</p>
<div class="lb-trans"><p>公司第二季度总营收为 2.41 亿美元，超出分析师预期，但反映了后疫情时代持续面临的挑战。</p>
</div><h2>Two-year cash runway</h2>
<div class="lb-trans"><h2>两年现金储备</h2>
</div><p>The cash burn rate continues to be significant, with Moderna’s cash position declining to $10.8 billion as of June 30, 2024, down from $12.2 billion at the end of Q1.</p>
<div class="lb-trans"><p>现金燃烧速度仍然显著，截至 2024 年 6 月 30 日，Moderna 的现金头寸下降至 108 亿美元，较第一季度末的 122 亿美元下降。</p>
</div><p>With operating expenses still elevated, Moderna’s cash runway is projected to sustain the company for about two more years, putting pressure on management to deliver on its pipeline and drive revenue growth from new product launches.</p>
<div class="lb-trans"><p>随着运营费用仍然居高不下，Moderna 的现金储备预计将支撑公司约两年时间，这给管理层带来了压力，要求其推动产品管线并通过新产品推出推动营收增长。</p>
</div><p>The company’s valuation metrics suggest that while Moderna’s stock is not overvalued, the current market sentiment is cautious.</p>
<div class="lb-trans"><p>公司的估值指标表明，尽管 Moderna 的股票并未被高估，但当前市场情绪谨慎。</p>
</div><p>The stock’s price-to-earnings (P/E) ratio has been difficult to gauge given the company’s ongoing losses, but its enterprise value to revenue (EV/revenue) ratio of 4.16 indicates that investors are still assigning a premium to Moderna’s potential future growth, despite recent setbacks.</p>
<div class="lb-trans"><p>股票的市盈率（P/E）难以衡量，但其企业价值与营收（EV/营收）比率为 4.16，表明投资者仍在给予 Moderna 未来潜在增长溢价，尽管最近遭遇挫折。</p>
</div><p>As Moderna continues to face headwinds, including competitive pressures in the respiratory vaccine market and uncertainties surrounding its oncology and rare disease programs, the path ahead is fraught with challenges.</p>
<div class="lb-trans"><p>随着 Moderna 继续面临来自呼吸道疫苗市场竞争压力以及其肿瘤学和罕见疾病项目的不确定性，前方道路充满挑战。</p>
</div><p>Now, let’s examine what the charts have to say about Moderna’s stock price trajectory. The technical indicators may provide further insights into whether the recent decline represents a buying opportunity or signals continued downside risk.</p>
<div class="lb-trans"><p>现在，让我们来看看图表对 Moderna 股价走势的看法。技术指标可能进一步揭示最近的下跌是买入机会还是继续下行风险的信号。</p>
</div><h2>Will the $67 support hold?</h2>
<div class="lb-trans"><h2>67 美元支撑位能否保持？</h2>
</div><p>Moderna’s stock has seen an extended downtrend since peaking above $480 in late 2021. After crashing to below $70 in November last year, the stock experienced a strong medium-term rally that took it to $170 levels by May this year, but it has halved since then as it now trades below $80.</p>
<div class="lb-trans"><p>自 2021 年底股价飙升至 480 美元以上以来，Moderna 股价一直处于持续下跌趋势。去年 11 月暴跌至 70 美元以下后，股价经历了一轮强劲的中期反弹，使其在今年 5 月达到 170 美元水平，但自那时以来已经下跌了一半，目前交易在 80 美元以下。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/MRNA_2024-09-12_18-36-08-1024x555.png" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2024/09/MRNA_2024-09-12_18-36-08-1024x555.png"/></p>
<p>Source: TradingView</p>
<div class="lb-trans"><p>来源：TradingView</p>
</div><p>This recent swift down move has made Moderna’s stock weak across timeframes and today’s crash will further exacerbate it. Hence, investors looking at today’s move as a buying opportunity must exercise caution. A long position should only be considered if Moderna’s stock again sees support around $67, where it took support late last year.</p>
<div class="lb-trans"><p>最近的急剧下跌使 Moderna 股价在各个时间框架上变得疲弱，今天的暴跌将进一步加剧这种情况。因此，将今天的走势视为买入机会的投资者必须谨慎行事。只有在 Moderna 股价再次在去年底支撑位 67 美元附近得到支撑时，才应考虑持有多头头寸。</p>
</div><p>Traders who are bearish on the stock following today’s news should look for bouncebacks above $70 before initiating short positions. If the stock falls below its medium-term support at $67, it will get significantly weak and can crash to significantly lower levels.</p>
<div class="lb-trans"><p>根据今天的消息对该股持悲观态度的交易者应该寻找股价回升至 70 美元以上后再建立空头头寸。如果股价跌破 67 美元的中期支撑位，将会变得非常疲弱，并可能暴跌至更低水平。</p>
</div><p>The post Why is Moderna’s stock crashing today? Here's what we know appeared first on Invezz</p>
<div class="lb-trans"><p>本文来源于 Invezz</p>
</div>

为什么 Moderna 的股票今天暴跌？以下是我们掌握的信息